信達生物-B(01801.HK):抗LAG-3單克隆抗體I期臨牀研究在中國完成首例患者給藥
格隆匯12月6日丨信達生物-B(01801.HK)公佈,公司自主開發的重組全人源抗淋巴細胞活化基因3(LAG-3)單克隆抗體(IBI-110)的I期臨牀研究完成中國首例患者給藥。
公告顯示,該臨牀研究是一項在中國開展的評估IBI-110單藥或聯合達伯舒®(信迪利單抗注射液),重組全人源抗PD-1單克隆抗體,治療晚期惡性腫瘤受試者中的安全性、耐受性和初步抗腫瘤有效性的臨牀研究。
據悉,LAG-3是腫瘤免疫治療中最有前景和潛力的靶點之一。現時,國外已開展多個LAG-3靶向藥物的早期臨牀研究,初步結果顯示靶向LAG-3作為單藥療法或聯合抗PD-1/抗PD-L1抗體藥物均展現出一定的安全性和抗腫瘤有效性,特別是聯合療法有望發揮協同增強作用。因此,開發針對LAG-3靶點的藥物將為患者提供更新型、全面和有效的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.